Cure8 research brief
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, Ustekinumab, and IL-12/23 inhibitor. Use the original source link for the full details.
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Review the original publication for the complete reporting, methods, and context.
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
The study compares ustekinumab effectiveness between biologic‑naïve and biologic‑experienced Crohn’s patients and links clinical response to better quality of life and reduced anxiety — information relevant when...
Patients and clinicians using ustekinumab may be able to use an early (around 3 months) drug concentration to help predict short-term remission, while routine repeated monitoring later on may be less informative for...
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...
